Drug Profile
Research programme: sleep disorders therapies - Neurocrine Biosciences
Latest Information Update: 23 Feb 2011
Price :
$50
*
At a glance
- Originator Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 16 Feb 2005 Preclinical trials in Sleep disorders in USA (PO)